Supplementary Figure 4 from Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma

PDF file - 103 KB, A, CreERT2 Foxm1 fl/fl and p53 -/- thymic lymphoma cell viability at 0h and 24 hours following non, 5�M of ARF 26-44 peptide, 5�M of ARF 37-44 peptide or PBS treatment. B, Foci formation of CreERT2 Foxm1 fl/fl and p53 -/- sarcoma cells following PBS, 25�M of ARF 27-44 peptide, or ARF 36-44 peptide treatment. C, Cleaved-caspase 3 staining of CreERT2 Foxm1 fl/fl and p53 -/- sarcoma cells 24 hours after 25�M of ARF 27-44 peptide treatment.